Gastroenterology · Viral Hepatitis
The facts most likely to be tested
Hepatitis D virus is a defective RNA virus that requires the Hepatitis B surface antigen (HBsAg) for viral replication and assembly.
Coinfection occurs when a patient is infected with both HBV and HDV simultaneously, typically resulting in an acute, self-limited illness.
Superinfection occurs when a patient with chronic HBV is subsequently infected with HDV, leading to a high risk of fulminant hepatitis and rapid progression to cirrhosis.
Diagnosis of HDV is confirmed by the presence of anti-HDV antibodies and HDV RNA in the serum.
Patients with chronic HBV who experience a sudden clinical deterioration or a flare of liver enzymes should be screened for HDV superinfection.
Prevention of HDV is achieved through Hepatitis B vaccination, as HDV cannot infect individuals who are immune to HBV.
The primary treatment for chronic HDV infection is pegylated interferon-alpha, which is the only therapy currently recommended to suppress viral replication.
Vignette unlocked
A 34-year-old male with a history of chronic Hepatitis B presents to the clinic with jaundice, right upper quadrant pain, and ascites. He has been stable on antiviral therapy for years, but his ALT and AST levels have spiked significantly over the last month. Physical examination reveals scleral icterus and hepatomegaly. Laboratory studies show a significant increase in his HBsAg titers and the presence of anti-HDV IgM antibodies.
What is the most likely diagnosis for this patient's clinical deterioration?
Hepatitis D superinfection
The patient's history of chronic HBV combined with a sudden flare of liver enzymes and the presence of anti-HDV antibodies is classic for HDV superinfection, which is tested in Bet 3 and Bet 5.
Full handout
High yield triage
Etiology / Epidemiology
Requires Hepatitis B surface antigen (HBsAg) for replication. High risk in IV drug users and patients with chronic HBV.
Clinical Manifestations
Presents as superinfection or coinfection. Causes rapid progression to cirrhosis and fulminant hepatitis.
Diagnosis
Diagnosed via HDV RNA or anti-HDV IgM/IgG. Requires presence of HBsAg.
Treatment
Management focuses on Pegylated interferon-alpha. No effective antiviral therapy exists for HDV specifically.
Prognosis
High risk of decompensated cirrhosis and hepatocellular carcinoma.
Full handout
Epidemiology & Etiology
HDV is a defective RNA virus that requires the HBsAg envelope for viral assembly. It is primarily transmitted via parenteral routes, including IV drug use and sexual contact. Endemic regions include the Mediterranean, Middle East, and parts of South America.
Pertinent Anatomy
The virus targets hepatocytes exclusively. Infection leads to massive inflammatory destruction of the liver parenchyma, often resulting in bridging necrosis.
Pathophysiology
HDV acts as a viral parasite on HBV. Coinfection occurs when a patient is infected with HBV and HDV simultaneously, while superinfection occurs when HDV infects a chronic HBV carrier. Superinfection typically leads to a more severe, accelerated clinical course.
Clinical Manifestations
Patients often present with jaundice, right upper quadrant pain, and fatigue. Superinfection is characterized by a sudden acute flare in a previously stable chronic HBV patient. Watch for signs of fulminant hepatic failure, including encephalopathy and coagulopathy.
Diagnosis
The gold standard for active infection is HDV RNA via PCR. Serologic testing for anti-HDV IgM indicates acute infection, while anti-HDV IgG suggests past or chronic exposure. Always confirm the presence of HBsAg to establish the diagnosis.
Treatment
The only established therapy is Pegylated interferon-alpha for at least 48 weeks. Nucleoside analogs used for HBV are ineffective against HDV because they do not inhibit the HDV replication cycle. Liver transplantation is the definitive treatment for decompensated cirrhosis.
Prognosis
HDV infection significantly increases the risk of cirrhosis and hepatocellular carcinoma compared to HBV monoinfection. Patients require lifelong monitoring for liver cancer via ultrasound and alpha-fetoprotein levels.
Differential Diagnosis
Hepatitis B: HDV RNA negative
Hepatitis C: Anti-HCV positive
Autoimmune Hepatitis: Elevated ANA/ASMA
Wilson Disease: Low ceruloplasmin
Alcoholic Hepatitis: AST:ALT ratio > 2:1